Sanjeev Ravipudi, MD
Interventional Cardiology · Moberly, MONPI 1588657811
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (50.2%), speaking fees and education — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 63.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $30,227 and has fallen 83.9% since, to $4,862 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $307.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$70K
- Johnson & Johnson$30K
- Boston Scientific$4K
- Abiomed$1K
- Cardiovascular Systems Inc.$1K
- Philips North America LLC$1K
- plus $2K from 23 others
What the payments were for
- Consulting fees$6001%
- Speaking & faculty fees$27,94025%
- Travel & lodging$2,3432%
- Food & beverage$9,5199%
- Education$14,53913%
- Other$55,45050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 21 | $70,258 |
| Johnson & Johnson | 57 | $29,675 |
| Boston Scientific | 74 | $4,185 |
| Abiomed | 20 | $1,371 |
| Cardiovascular Systems Inc. | 16 | $1,247 |
| Philips North America LLC | 23 | $1,196 |
| Novartis | 33 | $328 |
| E.r. Squibb & Sons, L.L.C. | 25 | $321 |
| AstraZeneca | 14 | $274 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $220 |
| Amgen | 11 | $185 |
| Biotronik Inc. | 6 | $139 |
| Esperion Therapeutics, Inc. | 7 | $109 |
| Penumbra, Inc. | 1 | $108 |
| BD | 2 | $102 |
| Amarin Pharma, Inc. | 7 | $100 |
| Shockwave Medical, Inc | 1 | $96 |
| Bayer | 4 | $92 |
| Boehringer Ingelheim | 5 | $87 |
| Medtronic(2 entities) | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Stryker | 1 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Merck | 2 | $29 |
| Bard Access Systems, Inc. | 2 | $29 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Pfizer | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$36,522
- XARELTO$28,839
- VenaCure 1470 Pro$24,000
- EVLT$9,600
- JETSTREAM$1,477
- Impella$1,037
- Diamondback Peripheral$882
- GENERAL - THERAPIES$430
- AngioSculpt PCA$300
- Lasers$227
- GENERAL ATHERECTOMY$217
- Peripheral Orbital Atherectomy System$147
- IGT D Peripheral$134
- Penumbra System$108
- EMBLEM MRI S-ICD$106
How this compares
$110,391 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $227,378 |
| XareltoRivaroxaban | 257 | $190,198 |
| EntrestoSacubitril/Valsartan | 138 | $142,790 |
| Repatha SureclickEvolocumab | 44 | $44,921 |
| FarxigaDapagliflozin Propanediol | 64 | $40,906 |
| Praluent PenAlirocumab | 13 | $16,645 |
| VascepaIcosapent Ethyl | 28 | $11,588 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 127 | $2,661 |
| Irbesartan | 190 | $2,331 |
| ClopidogrelClopidogrel Bisulfate | 317 | $2,163 |
| Ezetimibe | 120 | $2,143 |
| Atorvastatin Calcium | 345 | $2,094 |
| Ranolazine ErRanolazine | 31 | $1,526 |
| Metoprolol Succinate | 117 | $1,240 |
| Amiodarone Hcl | 84 | $1,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $227,378268 claims |
| Johnson & JohnsonXarelto | $29,675 | $190,198257 claims |
| NovartisEntresto | $328 | $142,790138 claims |
| AstraZenecaFarxiga | $274 | $40,90664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Moberly
- Prasanna Manjini SengodanMoberly$17K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.